Medical Communication

March 2022: Meducom supports important publication on reduced cardiotoxicity after switch to another chemotherapy

By January 21, 2023 No Comments

Fluoropyrimidine chemotherapy is widely used in many solid tumours, but is associated with cardiotoxicity. In an international retrospective study (13 centres in 6 countries), it was shown that switching to another (newly registered in metastatic colorectal cancer) fluoropyrimidine can be an option to allow continuation of this essential component of chemotherapy and thus not lose a treatment line.

The colleagues at Meducom were asked to provide support with the development and editing of the manuscript of this pivotal study for a new indication of a drug in metastatic colorectal cancer.